Donepezil

Generic Name: Donepezil

Brand Names: Adlarity, Aricept, Namzaric

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉NO_₃

CAS Number: 120014-06-4

Unique Ingredient Identifier: 8SSC91326P

Background: In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication: Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions: Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Phase 2

Completed

Conditions: Dementia Alzheimer's Type

Interventions: Drug: SAR110894
Drug: placebo (for SAR110894)
Drug: Donepezil

First Posted Date: 2010-12-24

Last Posted Date: 2016-03-14

Lead Sponsor: Sanofi

Target Recruit Count: 291

Registration Number: NCT01266525

Locations: 🇺🇸
Investigational Site Number 840024, Costa Mesa, California, United States
🇺🇸
Investigational Site Number 840041, Gilbert, Arizona, United States
🇵🇱
Investigational Site Number 616004, Bydgoszcz, Poland

and more 79 locations

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aricept®
Drug: Donepezil Hydrochloride

First Posted Date: 2010-12-15

Last Posted Date: 2011-02-21

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 26

Registration Number: NCT01260922

Locations: 🇺🇸
PRACS Institute, Ltd., East Grand Forks, Minnesota, United States

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aricept®
Drug: Donepezil Hydrochloride

First Posted Date: 2010-12-15

Last Posted Date: 2011-02-21

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 26

Registration Number: NCT01260948

Locations: 🇺🇸
PRACS Institute, Ltd., East Grand Forks, Minnesota, United States

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: donepezil hydrochloride

First Posted Date: 2010-12-02

Last Posted Date: 2023-07-24

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 894

Registration Number: NCT01251718

Effect of Donepezil on Smoking

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2010-12-01

Last Posted Date: 2019-07-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT01250977

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

Phase 3

Completed

Conditions: Alzheimer Type Dementia

Interventions: Drug: Aricept
Drug: INM-176

First Posted Date: 2010-11-22

Last Posted Date: 2011-06-13

Lead Sponsor: Whanin Pharmaceutical Company

Target Recruit Count: 280

Registration Number: NCT01245530

Locations: 🇰🇷
Whanin Pharm.Co.,Ltd., Seoul, Moonjung, Korea, Republic of

Scopolamine Challenge Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-05212377
Drug: Donepezil
Drug: scopolamine

First Posted Date: 2010-10-04

Last Posted Date: 2018-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT01213355

Locations: 🇫🇷
Pfizer Investigational Site, Rennes, France

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

Completed

Conditions: Biomarkers, Pharmacological

Interventions: Drug: Huperzine A
Other: Placebo
Drug: Donepezil
Drug: Galantamine

First Posted Date: 2010-09-03

Last Posted Date: 2017-05-03

Lead Sponsor: U.S. Army Medical Research and Development Command

Target Recruit Count: 84

Registration Number: NCT01194336

Locations: 🇺🇸
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States

Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-384
Drug: placebo
Drug: donepezil

First Posted Date: 2010-06-04

Last Posted Date: 2013-01-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 267

Registration Number: NCT01137526

Locations: 🇿🇦
Site Reference ID/Investigator# 45584, Belville, South Africa
🇷🇺
Site Reference ID/Investigator# 37944, Moscow, Russian Federation
🇬🇧
Site Reference ID/Investigator# 36327, Bath, United Kingdom

and more 27 locations

Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: donepezil hydrochloride

First Posted Date: 2010-05-24

Last Posted Date: 2018-11-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 10238

Registration Number: NCT01129596

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy